Table 2.
Pathologic response of three neoadjuvant schedules
| Overall (N = 253) | NAC.NICB (N = 98) | NAC (N = 107) | NICB (N = 48) | p value | |
|---|---|---|---|---|---|
| Pathological response | 0.002 | ||||
| CR | 50 (19.8%) | 31 (31.6%) | 12 (11.2%) | 7 (14.6%) | |
| PR | 72 (28.5%) | 28 (28.6%) | 34 (31.8%) | 10 (20.8%) | |
| SD | 100 (39.5%) | 31 (31.6%) | 43 (40.2%) | 26 (54.2%) | |
| PD | 31 (12.3%) | 8 (8.2%) | 18 (16.8%) | 5 (10.4%) | |
| CR response | 0.001 | ||||
| CR | 50 (19.8%) | 31 (31.6%) | 12 (11.2%) | 7 (14.6%) | |
| Non-CR | 203 (80.2%) | 67 (68.4%) | 95 (88.8%) | 41 (85.4%) | |
| Binary response | 0.007 | ||||
| Responder (CR + PR) | 122 (48.2%) | 59 (60.2%) | 46 (43.0%) | 17 (35.4%) | |
| Nonresponder (SD + PD) | 131 (51.8%) | 39 (39.8%) | 61 (57.0%) | 31 (64.6%) | |
| DCR response | 0.153 | ||||
| DCR | 222 (87.7%) | 90 (91.8%) | 89 (83.2%) | 43 (89.6%) | |
| Non-DCR | 31 (12.3%) | 8 (8.2%) | 18 (16.8%) | 5 (10.4%) |
NAC.NICB: combination of neoadjuvant chemotherapy and immunotherapy; NAC: neoadjuvant chemotherapy; NICB: neoadjuvant immunotherapy; CR: complete response; PR: partial response; SD: stable disease; PD: progression disease. DCR: disease control rate.